ACTON, Mass., March 19, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, ...
As Americans flock to nearby orchards for festive bouts of autumn apple picking, Insulet is celebrating a particularly bountiful stateside Apple harvest itself. The diabetes devicemaker has earned FDA ...
Insulet (($PODD)) announced an update on their ongoing clinical study. Insulet Corporation has announced a new clinical study titled ‘Omnipod 5 – ...
Insulet Corporation PODD continues to gain on solid prospects in the diabetes market. The company is progressing well with respect to its four-pillar strategy. The stock carries a Zacks Rank #2 (Buy).
Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock – anytime.
Insulet has secured an FDA clearance for its latest tubeless insulin pump, the Omnipod 5, a patch-like device capable of adjusting daily doses to changes in the wearer’s blood sugar levels. Designed ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
Insulet Corporation PODD recently announced positive results from the first pivotal study for the Omnipod 5 Automated Insulin Delivery System. The finding of the study suggests that Omnipod 5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback